DaShenLin Pharmaceutical Group Co., Ltd. (603233.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 18.25

From 52W high−18.38%

Volume11.61M

Market capCNY 19.77B

P/E (TTM)16.0x

P/S (TTM)0.8x

Div yield4.52%

Key dataSep 18, 2026

Open

CNY 18.25

From 52W high

−18.38%

Volume

11.61M

Market cap

CNY 19.77B

ValuationView details →

P/E (Fwd)

14.3x

EV/EBITDA

7.5x

P/E (TTM)

16.0x

RSI (14)

52.6

MomentumView details →

1D Return

−1.70%

YTD Return

+4.31%

ValuationView details →

P/E (Fwd)

14.3x

P/E (TTM)

16.0x

EV/EBITDA

7.5x

EV/Sales

0.7x

P/S (TTM)

0.8x

P/B (TTM)

2.8x

ProfitabilityView details →

Gross Margin

34.59%

Net Margin

4.67%

EBITDA Margin

8.70%

ROE (TTM)

16.34%

ROA (TTM)

4.79%

Asset Turnover

1.03x

GrowthView details →

Revenue YoY

+3.07%

EPS YoY

+32.32%

FCF YoY

+68.99%

Revenue CAGR 3Y

+8.98%

EPS CAGR 3Y

+5.88%

EBITDA YoY

—

MomentumView details →

1D Return

−1.70%

YTD Return

+4.31%

1Y Return

+6.00%

RSI (14)

52.6

vs 50D SMA

+0.07%

vs 200D SMA

+1.53%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

0.93x

Quick Ratio

0.64x

Div Yield

4.52%

Div Rate

CNY 0.83

Div Growth 1Y

+4.84%

EarningsView details →

EPS (Actual)

CNY 0.36

EPS Surprise

20.82%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.34

Avg Surprise (4Q)

20.82%

Rev Surprise

−6.15%

Financials snapshotView financials →

Revenue (TTM)

27.52B

Net Income (TTM)

1.29B

Op. CF (TTM)

4.55B

Next earningsOct 29, 2026 →

Latest newsMore news →

Dashenlin's board proposed a cash dividend of 0.41 yuan per share (including tax) for the first half of 2026.27d ago

Dashenlin announced its first-half 2026 results: revenue of 13.991 billion yuan, up 3.46% year-on-year; net profit attributable to shareholders of 927 million yuan, up 16.10% year-on-year.27d ago

Similar companies

Metis Techbio-p07666.HK 康希诺688185.SH United Therapeutics CorporationUTHR Genmab A/SGMAB Keymed Biosciences Inc.02162.HK Shanghai Junshi Biosciences Co., Ltd.01877.HK Find similar companies →

Latest newsMore news →

Dashenlin's board proposed a cash dividend of 0.41 yuan per share (including tax) for the first half of 2026.27d ago Dashenlin announced its first-half 2026 results: revenue of 13.991 billion yuan, up 3.46% year-on-year; net profit attributable to shareholders of 927 million yuan, up 16.10% year-on-year.27d ago